Epitalon
Also known as: Epithalon · Epithalamin (peptide fragment) · Ala-Glu-Asp-Gly
Khavinson lineage research base; approved in Russia; no Western RCTs; no documented serious AEs; replication outside originating group is limited.
Rating per Panya's data-first method, not regulator endorsement. The mechanism, dose, and risk sections below carry the underlying data.
Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by the Khavinson lab in St Petersburg as a fragment of the natural pineal-gland peptide complex. Heavily researched within Russia, sparsely replicated outside it, sold globally as a research peptide for longevity and circadian-rhythm support.
Last reviewed · Panya.health editorial
Panya scores vendors against an 11-signal rubric. Vendors at or above 70 out of 100 are routable; below 70 are documented but get no Panya affiliate link. For prescription peptides like Mounjaro and Wegovy, Panya routes today through licensed clinicians. For research peptides like Epitalon, vendor scorecards land in a follow-up sprint after legal review and payment processor selection. Until then, the page surfaces commonly-mentioned vendor names so adults can do their own diligence. We do not yet earn commission on any Epitalon vendor.
Not medical advice. Epitalon is not approved for human medical use in most jurisdictions. The data below is what users do; it is not what regulators have validated. You decide your risk profile.
What it does, and how
Epitalon was derived in the 1980s and 1990s from epithalamin, a peptide preparation extracted from bovine pineal glands. Vladimir Khavinson's group at the St Petersburg Institute of Bioregulation and Gerontology proposed that Epitalon acts as a peptide bioregulator: it crosses cell membranes, binds DNA in the nucleus, and modulates expression of genes involved in melatonin synthesis, telomerase activity, and circadian gene regulation. Khavinson and colleagues report telomerase upregulation in human somatic cells (Khavinson 2003), lifespan extension in murine models (Anisimov 2010), and reduced cardiovascular events in 110-patient elderly cohorts (Korkushko 2007). Most published evidence comes from the Khavinson group; independent replication outside the originating lab is limited.
Typical practice
Community practice runs 5 to 10 mg subcutaneous daily, in cycles of 10 to 20 days, repeated 2 to 4 times per year. Some users intramuscular; some intranasal (claimed but not pharmacokinetically characterised). Khavinson's clinical research used 1 to 10 mg per day depending on the trial. Reconstitution is typically 5 to 10 mg vial in 2 to 3 mL bacteriostatic water. There is no regulator-validated dosing protocol; everything in this paragraph reflects what users and Khavinson cohorts do, not a pharmacopoeia. Cycling rationale is theoretical (avoid receptor desensitisation) and not empirically validated.
The dosing above is community practice, not a regulator-validated protocol. Trial-validated dosing for Epitalon in humans does not exist for most use cases listed.
Risks and contraindications
Reported side effects in user logs and Khavinson cohort data are mild: injection-site irritation, occasional drowsiness or vivid dreams consistent with the melatonin-pathway claims. Telomerase upregulation has been documented in human somatic cells in the Khavinson 2003 paper; tumour cells frequently exploit telomerase reactivation as a proliferation mechanism, which leaves an open question about whether exogenous telomerase-modulating peptides could affect tumour biology in humans (no clinical safety data in oncology cohorts either direction). Long-term cardiovascular and metabolic safety outside the Khavinson cohorts is not characterised in the literature. No trial data exists in pregnancy or lactation cohorts. Drug interactions have not been formally studied. Independent replication of the Khavinson findings outside the originating research group is limited.
Where this stands legally
Not FDA-approved for any indication. Sold legally as a research chemical 'not for human consumption.' Customs scrutiny on personal-import peptides has tightened; small-quantity research-purpose imports occasionally still clear.
Not on the MHRA approved list. MHRA does not regulate research peptides per se; sale is technically lawful but human use is medically unsupervised. WADA does not currently list Epitalon as prohibited.
Not approved by EMA. Research peptide market is unregulated. Cross-border imports occasionally seized depending on member state and customs interpretation.
TGA Schedule 4 (prescription-only) for injectable peptides not on the approved list. Personal-use peptide imports actively investigated. Importation without a prescription is risky.
Not approved by Thai FDA. Available through research-peptide vendors and some longevity-clinic channels. No formal enforcement against personal use; quality and source vary widely.
HSA classifies injectable peptides without product registration as prescription-controlled. Sold in licensed longevity clinics under physician supervision; unlicensed personal imports get seized.
Sold through wellness clinics in HCMC and Hanoi serving the longevity-curious expat market. Vietnam Drug Administration enforcement is light on research peptides; quality is the main risk vector.
Originating jurisdiction. Khavinson's institute holds patents and the peptide has been used in Russian gerontology clinics for 20+ years. Imports of Russian-manufactured Epitalon to other regions vary in legality.
Where users say they source it
Names below are sourced from community discussion. None are currently scored against the Panya 11-signal rubric. Panya does not earn commission on any of these. You can search them yourself; treat the list as a starting point for your own diligence, not an endorsement.
- Russian research-peptide suppliers (Khavinson-lineage, Russian language sites)Pending Panya 11-signal audit
- International research-chem vendors with COA per lot (variable quality, audit the COA)Pending Panya 11-signal audit
- Compounding pharmacies in jurisdictions where Schedule 4 + prescription apply (rare)Pending Panya 11-signal audit
- SEA longevity clinics in TH and SG (with physician supervision in SG, often without in TH)Pending Panya 11-signal audit
Full vendor scorecards for Epitalon land in a follow-up sprint after lawyer review and payment processor selection. We will not route users to any vendor that scores below 70 on the rubric.
Papers worth reading directly
- Khavinson VKh, Bondarev IE, Butyugov AA. (2003) Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med →
- Anisimov VN, Khavinson VKh. (2010) Peptide bioregulation of aging: results and prospects. Biogerontology →
- Khavinson VKh et al. (2014) Peptide regulation of cell differentiation, gene expression, and protein synthesis. Bull Exp Biol Med →
- Korkushko OV, Khavinson VKh, Shatilo VB. (2007) Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people. Bull Exp Biol Med →
Adjacent reading
Track Epitalon in your peptide journal.
Panya users log their full stack at panya.health/journey. Public-by-default with per-entry privacy controls. Vote-validated by the community.